DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

Wedbush Maintains Outperform on Kala Pharmaceuticals, Raises Price Target to $52

Wedbush analyst Lina Moussatos maintains Kala Pharmaceuticals (NASDAQ:KALA) with a Outperform and raises the price target from $51 to $52.

Benzinga · 03/10/2020 13:09

Wedbush analyst Lina Moussatos maintains Kala Pharmaceuticals (NASDAQ:KALA) with a Outperform and raises the price target from $51 to $52.